↓ Skip to main content

Central delivery of iodine-125–labeled cetuximab, etanercept and anakinra after perispinal injection in rats: possible implications for treating Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)

Mentioned by

news
2 news outlets

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
29 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Central delivery of iodine-125–labeled cetuximab, etanercept and anakinra after perispinal injection in rats: possible implications for treating Alzheimer’s disease
Published in
Alzheimer's Research & Therapy, November 2015
DOI 10.1186/s13195-015-0149-7
Pubmed ID
Authors

Megan E. Roerink, Rob JM Groen, Gerben Franssen, Bianca Lemmers-van de Weem, Otto C. Boerman, Jos WM van der Meer

Abstract

Alzheimer's disease is a debilitating condition, and the search for an effective treatment is ongoing. Inflammation, in reaction to amyloid deposition, is thought to accelerate cognitive decline. With tumor necrosis factor α being an important proinflammatory cytokine, a recent trial investigated the effect of the tumor necrosis factor α inhibitor etanercept after peripheral administration in patients with Alzheimer's disease. Although there was no significant effect, others have claimed spectacular effects of etanercept after perispinal injection. In the present study, the central delivery of drugs with a large molecular weight was evaluated after injection in the cervical perispinal region in rats. If successful, this strategy might increase therapeutic options for patients with Alzheimer's disease. Nine male Sprague-Dawley rats were given injections of iodine-125-labeled cetuximab (146 kDa), etanercept (51 kDa), and anakinra (17 kDa). Each radioiodinated drug was injected in the perispinal region in two rats and into the dorsal tail vein in one rat. Directly after injection, the rats were placed in a head-down position for 3 minutes to direct blood flow into the valveless vertebral venous system. A single-positron emission computed tomography scan was acquired starting 5 minutes after injection, subsequently the rats were euthanized and bio-distribution was determined.   Intracranial delivery of the radiolabeled drugs could not be visualized in all but one of the rats. Injected drugs accumulated locally in the perispinal region. In this study, no evidence could be found for the delivery of drugs to the central nervous system after perispinal injection. Additional research is needed before this treatment can be used in patients with Alzheimer's disease.

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 29 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 21%
Student > Master 4 14%
Professor 3 10%
Student > Bachelor 3 10%
Unspecified 2 7%
Other 6 21%
Unknown 5 17%
Readers by discipline Count As %
Medicine and Dentistry 5 17%
Agricultural and Biological Sciences 4 14%
Neuroscience 3 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Unspecified 2 7%
Other 4 14%
Unknown 9 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 November 2015.
All research outputs
#802,822
of 11,426,369 outputs
Outputs from Alzheimer's Research & Therapy
#106
of 452 outputs
Outputs of similar age
#26,574
of 250,261 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#17
of 18 outputs
Altmetric has tracked 11,426,369 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 452 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.4. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,261 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.